The ICI Ipilimumab (a human antibody targeting the cytotoxic T-lymphocyte-associated protein 4, CTLA4) was the first to demonstrate an OS benefit among patients with metastatic melanoma and was approved by the FDA in the beginning of 2011 (5–7). The gene discussed is CTLA4; the disease is metastatic melanoma.